Navigation Links
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Date:12/3/2008

ts 2 years of age and older. Further studies are being performed to determine the long-term benefits and risks of Exjade.

Exjade is contraindicated in patients with hypersensitivity to deferasirox or to any other component of Exjade.

Cases of acute renal failure, some with a fatal outcome, have been reported following the post-marketing use of Exjade. Most of the fatalities occurred in patients with multiple comorbidities and who were in advanced stages of their hematologic disorders. There have also been reports of renal tubulopathy in patients treated with Exjade. Give particular attention to monitoring serum creatinine in patients who: are at increased risk of complications, have pre-existing renal conditions, are elderly, have comorbid conditions, or are receiving medicinal products that depress renal function.

Assess serum creatinine in duplicate before initiating therapy to establish a reliable pretreatment baseline, due to variations in measurements. Monitor serum creatinine monthly thereafter. In patients with additional renal risk factors (those who are at increased risk of complications, have pre-existing renal conditions, are elderly, have comorbid conditions, or are receiving medicinal products that depress renal function), monitor serum creatinine weekly during the first month after initiation or modification of therapy and monthly thereafter. Nonprogressive increases in serum creatinine have been noted in 38% of Exjade-treated patients, compared to 14% of deferoxamine-treated patients in Study 1 and 36% vs 22%, respectively in Study 3, and appear to be dose related. These increases were within the normal range in 94% of patients. Exjade dosages were adjusted when serum creatinine elevations were detected during the study.

Consider dose reduction, interruption, or discontinuation for elevations in serum creatinine. For adult patients, reduce daily dose of Exjade by 10
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
9. St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia
10. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
...  Volcano Corporation (NASDAQ: VOLC ), a leading ... guidance tools designed to enhance the treatment of coronary ... be participating in the 30th Annual J.P. Morgan Healthcare ... by Scott Huennekens, president and chief executive officer, will ...
... (NASDAQ: OPTR ) today announced that the Company ... on Tuesday, January 10 at 8:30 AM Pacific Time. ... live audio webcast of the presentation will be accessible on ... .   Replays of the presentation will be available at ...
Cached Medicine Technology:
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... Calif.) The risk of pregnancy among women using ... is more than 10 times greater over a 10-year ... a study by researchers at Yale University and UC ... the medical journal Contraception , the study found ... method marketed under the brand name Essure. , ...
(Date:4/22/2014)... Washington, DC (April 22, 2014) The International ... May 22-26 in Seattle, Washington. The theme of ... life" means in a networked and digital society. ... and attended by over 2,200 Communication scholars representing ... largest scholarly international communication conference in the world. ...
(Date:4/22/2014)... is the standard measurement for assessing glycemic control over ... are typically measured every few months in a laboratory, ... accurately estimates A1c using self-monitored blood glucose (SMBG) readings, ... ( DTT ), a peer-reviewed journal from Mary Ann ... the DTT website at http://www.liebertpub.com/dtt . ...
Breaking Medicine News(10 mins):Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... suggests , , FRIDAY, Nov. 21 (HealthDay News) -- The season ... asthma, new research suggests. , Babies born in autumn -- about ... almost a 30 percent increased risk of asthma compared to babies ... the first December issue of the American Journal of Respiratory ...
... not given adequate drug therapy. This is the result of ... rzteblatt International ( Dtsch Arztebl Int 2008; 105[45]: ... this prospective, one-year survey. , 512 doctors in Germany took ... of whom 89.2% suffered from one or more cardiovascular diseases ...
... HUN ) today announced that its Founder and Chairman, ... American Cancer Society to,receive this year,s Medal of Honor, its ... who have made outstanding contributions to the,fight against cancer. , ... and his wife Karen Huntsman have "raised or,personally contributed over ...
... Nov. 21 Massachusetts Mutual Life,Insurance Company (MassMutual) ... Officers. , ... Vice President,and Chief Investment Officer, will assume the ... who remains Chairman and Chief Executive,Officer. Additionally, Mr. ...
... STOUGHTON, Mass., Nov. 21 Cardiosolutions, Inc.,( http://www.cardiosolutionsinc.com ... M.D., Ph.D. to the position of Chief Surgical ... Center for Aortic Surgery and Director of the,Marfan ... Department of,Thoracic and Cardiovascular Surgery at Cleveland Clinic. ...
... located in,Pittsburgh PA, and a subsidiary of Draeger, ... it believes are unsubstantiated allegations from,Sperian Respiratory Protection ... the popular Draeger PSS7000 SCBA (Self-Contained Breathing,Apparatus) used ... Draeger has a strong respect for intellectual ...
Cached Medicine News:Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3Health News:Jon M. Huntsman Receives American Cancer Society Medal of Honor 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 3Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 4Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 5Health News:Cardiosolutions Names Dr. Lars Svensson Chief Surgical Officer 2Health News:Draeger Counters What It Believes Are Unsubstantiated Allegations of Patent Infringement by Sperian 2
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
A gentle yet highly effective corneal rust ring remover with Alger brush of 1mm burr. Runs off 1 x AA battery, no switches, simply spin mandrel to operate....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings. Ophtho-burr handpiece only. Battery powered handpiece....
Medicine Products: